Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Mean reduction in LIGHT levels of appro